Q2 FY27 call: both IPO-funded acquisitions complete, Saicriti injectable plant targeted for July 2027
Transcript of the Q2 FY27 earnings call held on 2nd November 2026 shared with the exchanges.
By ScoutQuest · · 4 min read
- Revenue from operations
- INR196 crores for the quarter; H1 FY27 INR376 crores, about half of the FY27 target of INR750 crore
- Gross margin
- 47.5% in Q2; management expects to keep it above 45%
- EBITDA / PAT
- EBITDA INR41 crores, PAT INR10.5 crore
The transcript covers the Q2 and H1 FY27 earnings call held on 2nd November 2026, addressed by Chairman and Managing Director Anil Kumar Karusala and Mark Thulborne, CEO of Noumed, and hosted by Emkay Global Financial Services. The Chief Financial Officer could not join because of a personal health emergency, and the Chairman presented the financials.
Quarterly performance
- Revenue from operations rose sequentially to INR196 crores.
- H1 FY27 revenue was INR376 crores, which management described as around half of its INR750 crore target for FY27. The company has historically had a stronger second half, and management said it is ahead of plan.
- Gross margin improved to 47.5%, helped by working through higher-cost inventory, stricter first-in-first-out controls and a new ERP system.
- EBITDA was INR41 crores, with margins expanding from the previous quarter as employee and other operating costs grew more slowly than revenue.
- Profit after tax was INR10.5 crore, held up despite higher depreciation and amortisation after capitalisation of Noumed assets and amortisation of molecules acquired with Sai Prathyak.
Guidance given on the call
- Gross margin is expected to stay above 45% in the coming quarters.
- The FY27 revenue target remains INR750 crore.
- The new Saicriti injectable facility is targeted for completion in July 2027, with exports expected from FY28 and Europe from FY29.
- The Unit III block at Bhongir is to start from December 2026, with output ramping up from Q4 FY27.
- The R&D subsidiary is expected to begin generating revenue from FY28.
Use of IPO proceeds
- Shareholders approved the variation in the use of IPO proceeds and both transactions are now complete.
- INR98.8 crores of IPO proceeds are being invested, with the company taking a controlling stake in each asset.
- Management said the purpose of the fund raise is unchanged: EU GMP-compliant injectable capacity for regulated markets and a dedicated research and development platform. Only the manner of execution changed, and it said it has acquired materially larger assets for the same outlay.
- A residual minority stake in the R&D subsidiary may be acquired through a right of first refusal at the same valuation.
Saicriti injectable facility
- Located at Gummadidala, outside the Outer Ring Road; foundation work is underway and construction has been accelerated.
- Layout design is complete and purchase orders have been placed for all four process lines.
- Being built to EU GMP and US FDA standards, and it adds two new capabilities: lyophilisation and GLP-1 manufacturing.
- The existing domestic critical care franchise will also be manufactured there, and Units I and II at Jeedimetla will be discontinued once it is commissioned.
- The balance equity is funded by the promoters of Saicriti, with the remainder through project debt.
Sai Prathyak Laboratories
- The majority stake was acquired and the company has been renamed Sai Prathyak Laboratories; all group R&D is now consolidated there.
- It brings a team of scientists with experience in lyophilised, liposomal and nano-based complex injectables and oncology, plus a large portfolio of molecules and SKUs.
- Its main value to the group is technology transfer: products already developed can move to the new Saicriti facility, saving development time.
- It had no revenue stream so far; R&D and CRO development contracts with external clients are to begin from the next quarter.
Unit III expansion and exports
- The expansion at Bhongir is almost complete; the new block starts from December 2026 and adds ointment manufacturing, a dedicated high-speed capsule filling line, and high-speed liquid oral manufacturing and filling lines.
- Most of the additional volume is intended for Australia and New Zealand, and bulk tablets will be supplied from India while the Adelaide facility prepares to start production.
- Australia remained the largest export destination but its share of export revenue moderated from the previous quarter, returning to the planned mix between Australia and other markets.
- The Philippines share of export revenue rose, with new cardiovascular products added during the quarter.
What to track
- Whether gross margin stays above 45%.
- Completion of the Saicriti facility by July 2027 and the start of the Unit III block from December 2026.
- Ramp-up of the new capacity aimed at Australia and New Zealand from Q4 FY27.
- Conversion of the R&D subsidiary into a revenue-generating business from FY28.
Also from Sai Parenterals
Board approves signing agreement to acquire majority stake in Bion Therapeutics via wholly owned subsidiary
16 Nov 2026
Sai Parenterals makes available audio recording of Q2 FY27 post-earnings conference call held 2nd November, 2026
2 Nov 2026
Sai Parenterals investor presentation: Q2 FY27 revenue jumps on Noumed consolidation as Rs. 571 crore capex builds
1 Nov 2026
More numbers
- Q2 FY27 revenue from operationsINR196 crores
- H1 FY27 revenue from operationsINR376 crores
- FY27 revenue targetINR750 crore
- Q2 FY27 gross margin47.5%
- Guided gross margin floor for coming quarters45%
- Q2 FY27 EBITDAINR41 crores
- Q2 FY27 profit after taxINR10.5 crore
- IPO proceeds being invested in the two acquisitionsINR98.8 crores
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.